Categories: Technology

Quadient Announces Supplier Agreement with Vizient, Enhancing Access to the U.S. Healthcare Market

Quadient Announces Supplier Agreement with Vizient, Enhancing Access to the U.S. Healthcare Market

Quadient (Euronext Paris: QDT), a global automation platform powering secure and sustainable business connections, has entered into a supplier agreement with Vizient, the largest provider-driven healthcare performance improvement company in the U.S. Vizient’s diverse client base includes some of the country’s most prestigious hospitals and integrated health delivery networks. The agreement enhances opportunities for Quadient to serve healthcare providers across the continuum of care, offering contracted pricing for a wide range of the company’s digital software, mail and automated locker solutions.

Vizient provides network-powered insights into the critical areas of clinical, operational and spend management performance and empowers clients to deliver exceptional, cost-effective care. Serving more than 65% of U.S. acute care providers and more than 35% of the non-acute market, Vizient’s contract portfolio represents $140 billion in annual purchasing volume. Through the new contract, healthcare providers have greater access to Quadient’s cutting-edge solutions designed to enhance digital patient interactions, optimize the sending and receiving of mail and packages, improve operational efficiency, increase document security and ensure regulatory compliance.

“We are thrilled to be awarded a contract from Vizient to help healthcare organizations improve performance through more streamlined and automated workflows, leading to better patient and staff experiences” said Geoffrey Godet, CEO at Quadient. Our strategic approach to supply chain and procurement in the mailing and communications space is rooted in a comprehensive, assessment-based process that identifies key assets and opportunities to drive efficiency and transformation for healthcare providers. We are excited to support Vizient clients with innovative, results-driven solutions that enhance operational performance and elevate the overall healthcare experience.”

For more information about Quadient’s solutions and contract with Vizient, visit www.quadient.com and mail.quadient.com/en/healthcare-contracts/Vizient.

About Quadient®
Quadient is a global automation platform powering secure and sustainable business connections through digital and physical channels. Quadient supports businesses of all sizes in their digital transformation and growth journey, unlocking operational efficiency and creating meaningful customer experiences. Listed in compartment B of Euronext Paris (QDT) and part of the CAC® Mid & Small and EnterNext® Tech 40 indices, Quadient shares are eligible for PEA-PME investing. For more information about Quadient, visit http://www.quadient.com/en/.

Media Contacts
Joe Scolaro, Quadient
Global Press Relations Manager
+1 203-301-3673
jscolaro@quadient.com

Kiley Ribordy, Walker Sands
Senior PR Director
quadientpr@walkersands.com

GlobeNews Wire

Recent Posts

Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

February 06, 2026 16:01 ET  | Source: Ocular Therapeutix, Inc. BEDFORD, Mass., Feb. 06, 2026…

6 hours ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 06, 2026 16:01 ET  | Source: NewAmsterdam Pharma N.V. NAARDEN, The Netherlands and MIAMI,…

6 hours ago

Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery

New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing…

6 hours ago

The Ministry of Finance and the International Monetary Fund to launch tomorrow the second edition of the AlUla Conference for Emerging Market Economies

AlUla, Saudi Arabia, Feb. 7, 2026 /PRNewswire/ -- The second edition of the AlUla Conference…

6 hours ago

Roches fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint…

6 hours ago

Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

February 06, 2026 17:17 ET  | Source: Lexicon Pharmaceuticals, Inc. THE WOODLANDS, Texas, Feb. 06,…

6 hours ago